Could a cholesterol shot boost stroke recovery?
NCT ID NCT07540741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding evolocumab (a powerful cholesterol-lowering drug) to standard statin therapy helps people recover better after a stroke caused by hardening of the large arteries. Researchers will follow 1000 adults aged 18-80 for 90 days, comparing those who get the combination to those who get statin alone. The goal is to see if the combination leads to better daily function and fewer repeat strokes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evolocumab (a PCSK9 inhibitor) plus statin
What this could lead to
If successful, this could show that adding evolocumab to standard statin therapy helps more people recover better after a stroke caused by large-artery atherosclerosis.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. The benefit may be small, and there is a risk of side effects like injection-site reactions or muscle pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin, Heilongjiang, China, 150001
RECRUITINGHeilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••